Gilead just bought a cancer immunotherapy company for $12 billion
Reuters
Gilead, known for its HIV and hepatitis C drugs, has been growing a cash pile over the past few years since the approval of its hepatitis C drug, leading investors to speculate what company it might buy. Gilead's purchase of Kite is the first big deal the company's had since.
Kite's shares were up 29% on the news before markets opened on Monday.
Kite has been one of the companies leading development for a new form of highly personalized cancer treatment is called CAR T-cell therapy. It's a type of cancer immunotherapy - or a therapy that harnesses the body's immune system to take on cancer cells.
Short for chimeric antigen receptor T-cell therapy, CAR-T treatment takes a person's own cells, removes them from the body, re-engineers them, and then puts the cells back in the body where they can attack cancer cells. In July, an FDA panel voted in favor of approving one of these treatments made by Novartis. One of the panelists called it "most exciting thing I've seen in my lifetime." That therapy, a treatment for pediatric acute lymphoblastic lymphoblastic leukemia, is expected to get a decision from the FDA by October.
One month later, in November, Kite is expected to get an answer from the FDA regarding its CAR-T treatment for a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. In data Kite released in February, the company found that out of the 101 patients, 36% had a complete response to the treatment after six months.
Markets Insider
- I'm an interior designer. Here are 10 things in your living room you should get rid of.
- A software engineer shares the résumé he's used since college that got him a $500,000 job at Meta — plus offers at TikTok and LinkedIn
- Higher-paid employees looking for work are having a tough time, and it could be a sign of a shift in the workplace
- Apple clinches strong double-digit growth in India; CEO says incredibly exciting market
- Nifty hits record peak in early trade; Bajaj Finance jumps 6%
- Carbon Credits and Trading
- Rupee jumps 9 paise to 83.37 against US dollar in early trade
- Top 10 destinations to visit in India for nature and wildlife lovers in 2024
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market